Atopic Dermatitis

New phase 3 data indicates significant improvements in disease severity in children 1-11 years old with eosinophilic esophagitis.

Previous literature indicated a higher prevalence of eczema in children who live in areas with hard water, but this association was not explored in adults until now.

The topical therapy has been under investigation as a first-in-class therapy for this highly contagious skin condition.

Dr. Karan Lal provides an overview of laser therapy for acne, and speaks on the "phenomenal" responses observed in patients with the first and only FDA approved laser treatment, AviClear.

New 21-month data from the SUSTAIN trial found that patients with no history of biologic therapies responded well to secukinumab.

Investigators suggest parents and clinicians should be mindful of children with suspected ACD with a history of exposure to jewelry, clothing, and belts with cobalt.

Investigators say the increased risk of emergency room admissions and urgent healthcare use among patients with concomitant AD and asthma warrants a better understanding of disease interplay.

Previous research had resulted in conflicting results regarding the drug survival of guselkumab, which was shown to be highest among several biologics featured in this larger study.

Nearly 40% of patients with prurigo nodularis reached clearance or almost-clearance of skin lesions following treatment with nemolizumab.

Elizabeth A. Swanson, MD, and Raj. J. Chovatiya, MD, PhD, examine challenges in managing atopic dermatitis and explore the evolving treatment landscape.

Korey Capozza, MPH; Elizabeth A. Swanson, MD; and Taylor Capps share pearls for patients and their families managing atopic dermatitis.

Korey Capozza, MPH, highlights the importance of patient advocacy in the atopic dermatitis journey.

Despite the frequency in which the ARAs were detected, investigators noted that they were not associated with any noticeable patient outcomes.

The Acne-Q and the CompAQ instruments received an “A” recommendation by investigators, though evidence on content validity and other measurement properties were lacking.

New data from ECZTRA 6 show improved sleep quality, itch relief and quality of life among teenagers treating atopic dermatitis with the IL-13 inhibitor.

Raj J. Chovatiya, MD, PhD; Elizabeth A. Swanson, MD; Tina Capps; and Taylor Capps assess barriers in finding and obtaining atopic dermatitis treatments.

Elizabeth A. Swanson, MD, discusses the safety and efficacy of dupilumab in treating moderate to severe atopic dermatitis, and Taylor Capps shares her journey with dupilumab from insurance approvals through receiving treatment.

Results from a cross-sectional survey suggest consistent patient preferences for treatment outcomes and means of administration.

Dr. Cohen details the latest study from Yale, which indicated that women from lichen sclerosus had increased risk of developing depression and anxiety.

Several prominent dermatologists sound off on the implications of this decision, JAK inhibitors, and how this approval will aid providers in redefining alopecia areata as an autoimmune disorder rather than simply a cosmetic condition.

Investigators suggested that antipruritic therapies be offered to patients with psoriasis, as most psoriasis therapies did not result in any improvements.

Egeberg and colleagues suggested that future research could study why physicians would choose to increase dosing – which as the study suggested, influenced cost- rather than switching treatments.

The investigative team believed these associations were attributable to the chronic nature of the disease as well as negative associations with quality of life and sexual function.

Data from the first human trial of the topical cream suggests a new approach to treating cutaneous warts in adults.